Molecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil

Página do item simplificado
dc.contributor.authorPeres, Stela Verzinhasse
dc.contributor.authorArantes, Paola Engelmann
dc.contributor.authorFagundes, Marcela de Araújo
dc.contributor.authorAb'Saber, Alexandre Muxfeldt
dc.contributor.authorGimenes, Daniel Luiz
dc.contributor.authorCurado, Maria Paula
dc.contributor.authorVieira, René Aloisio da Costa
dc.contributor.institutionFundação Oncocentro de São Paulo
dc.contributor.institutionCancer Epidemiology and Statistics Group - São Paulo (SP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionGrupo Oncoclínicas de São Paulo
dc.contributor.institutionGraduate Program in Oncology - Barretos (SP)
dc.date.accessioned2023-07-29T14:02:11Z
dc.date.available2023-07-29T14:02:11Z
dc.date.issued2023-01-01
dc.description.abstractOBJECTIVE: This study aimed to analyze the prognosis of women with breast cancer by molecular subtypes, sociodemographic variables, and clinical and treatment characteristics. METHODS: This hospital-based retrospective cohort study analyzed 1,654 women over 18 years of age diagnosed with invasive breast cancer from 2000 to 2018. Data were extracted from Brazil's Oncocenter Foundation of São Paulo. The variables analyzed were age, histology, molecular subtypes, clinical staging, treatment type, and diagnosis-to-treatment time. Cox regression analysis was applied to estimate death risk. RESULTS: Women with HER-2-positive (nonluminal) and triple-negative molecular subtypes were more than twice more likely to be at risk of death, with adjusted hazard ratio - HRadj=2.30 (95% confidence interval - 95%CI 1.34-3.94) and HRadj=2.51 (95%CI 1.61-3.92), respectively. A delayed treatment associated with an advanced clinical stage at diagnosis increased fourfold the risk of death (HRadj=4.20 (95%CI 2.36-7.49). CONCLUSION: In summary, besides that interaction between advanced clinical stage and longer time between diagnosis and treatment, HER-2-positive (nonluminal) and triple-negative phenotypes were associated with a worse prognosis. Therefore, actions to reduce barriers in diagnosis and treatment can provide better outcome, even in aggressive phenotypes.en
dc.description.affiliationFundação Oncocentro de São Paulo Department of Information and Epidemiology - São Paulo (SP)
dc.description.affiliationA.C. Camargo Cancer Center Centro International de Pesquisa Cancer Epidemiology and Statistics Group - São Paulo (SP)
dc.description.affiliationFundação Oncocentro de São Paulo Department of Pathology - São Paulo (SP)
dc.description.affiliationUniversidade de São Paulo Clinical Hospital - São Paulo (SP)
dc.description.affiliationGrupo Oncoclínicas de São Paulo Department of Mastology - São Paulo (SP)
dc.description.affiliationUniversidade de São Paulo Faculty of Medicine of Botucatu Graduate Program in Obstetrics and Gynecology - Botucatu (SP)
dc.description.affiliationHospital do Câncer de Barretos Graduate Program in Oncology - Barretos (SP)
dc.format.extente230028
dc.identifierhttp://dx.doi.org/10.1590/1980-549720230028
dc.identifier.citationRevista brasileira de epidemiologia = Brazilian journal of epidemiology, v. 26, p. e230028-.
dc.identifier.doi10.1590/1980-549720230028
dc.identifier.issn1980-5497
dc.identifier.scopus2-s2.0-85160590877
dc.identifier.urihttp://hdl.handle.net/11449/249093
dc.language.isoeng
dc.relation.ispartofRevista brasileira de epidemiologia = Brazilian journal of epidemiology
dc.sourceScopus
dc.titleMolecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazilen
dc.typeArtigo
unesp.author.orcid0000-0001-8120-2920[1]
unesp.author.orcid0000-0003-3813-3178[2]
unesp.author.orcid0000-0003-0662-4810[3]
unesp.author.orcid0000-0002-6371-177X 0000-0002-6371-177X[4]
unesp.author.orcid0000-0003-0383-1849[5]
unesp.author.orcid0000-0001-8172-2483[6]
unesp.author.orcid0000-0003-2014-9016 0000-0003-2014-9016[7]

Arquivos

Coleções

Artigos - Ginecologia e Obstetrícia - FMB